European Companies Search Engine
EU funding (€6,000,000): Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope Hor1 May 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope
Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such as insufficient knowledge on risk factors that contribute to PCa and on patient characteristics (including genetic profiles) that could facilitate patient stratification. Finally, there is lack of meaningful engagement of all key stakeholders, while the knowledge currently gained from clinical practice and real life data is not being fed back into PCa patients’ care pathways. There is thus a need for better definition of PCa across all stages, improved patient’s stratification at diagnosis, and standardisation of PCa-related outcomes based on real life data. PIONEER’s unique dual approach is to first identify critical evidence gaps in PCa by respected Key Opinion Leaders, and then embark on a research priority setting exercise that reflects the needs of all key stakeholders in PCa management. To achieve this, PIONEER has brought together comprehensive datasets that consists of the most relevant prostate clinical trials and registries, large epidemiological cohorts, electronic heath records, and real-life data from different European (and non-European) patient populations. These unique data sets will be integrated, standardised, harmonised and analysed using approaches that are built on our experience of similar previous IMI projects i.e EMIF, and eTRIKS, and analysed using a unique set of methodologies and advanced analytics methods (OMOP, eHS). PIONEER has already performed a first PCa research priority setting survey, where major stakeholders were asked to identify the current unmet needs in PCa. The five most important open questions will be used as pilot studies to verify PIONEER’s research framework. As such, PIONEER’s deliverables will be outcome-driven, value-based and patient-centric, and relevant to all key stakeholders, as they would have been meaningfully involved from the inception of the project.
Funded Companies:
| Company name | Funding amount |
| Association Eisbm | €758,200 |
| Astellas Pharma Europe B.V. | €0.00 |
| Astrazeneca AB | €0.00 |
| BAYER AG | €0.00 |
| Cancer Intelligence Ltd. | €12,121.34 |
| Erasmus Universitair Medisch Centrum Rotterdam | €415,349 |
| €180,000 | |
| European Cancer Patient Coalition | €69,994 |
| European Organisation for Research AND Treatment OF Cancer Aisbl | €16,000.00 |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | €125,000 |
| Goeteborgs Universitet | €150,650 |
| HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF e. V. | €101,300 |
| IHE, Institutet FOR Halso- och Sjukvardsekonomi AB | €175,000 |
| IMS Information Solutions Medical Research Ltd. | €0.00 |
| Imperial College of Science Technology and Medicine | €200,000 |
| €31,250 | |
| Janssen Pharmaceutica N.V. | €0.00 |
| €0.00 | |
| King's College London | €359,000 |
| Labcorp Early Development Laboratories Ltd. | €0.00 |
| Lunds Universitet | €185,761 |
| NV SAS Institute SA | €0.00 |
| ORION Oyj | €0.00 |
| Pinsent Masons LLP | €188,800 |
| Sanofi-Aventis Recherche & Developpement | €0.00 |
| €797,439 | |
| Stichting Radboud Universitair Medisch Centrum | €124,922 |
| €25,078 | |
| €212,500 | |
| TECHNISCHE UNIVERSITAET DRESDEN | €125,000 |
| €400,000 | |
| The Ecancer Global Foundation | €37,333 |
| €409,303 | |
| €237,500 | |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | €150,000 |
| Universita Vita-Salute SAN Raffaele | €312,500 |
| VARIAN MEDICAL SYSTEM DEUTSCHLAND GmbH | €0.00 |
| €200,000 |
Source: https://cordis.europa.eu/project/id/777492
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Association Eisbm - EU funding (€6,000,000): Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
